Výsledky vyhledávání

Earlier News: 2019 - 2018 We help inventions grow! BACK TO LATEST NEWS i&i Prague is joining Hello Tomorrow Ecosystem, a global community boosting deep technology-based start-ups Read More Novel partnership for iBodies has been facilitated by i&i Prague and IOCB Tech managers Read More Revolutionary type of catheter raised €2 million from private investors Read More A novel early cancer diagnostics method has been developed at University of Pardubice, partnered with i&i Prague Read More DIANA Biotechnologies, a novel startup in the i&i Prague´s academic incubator Read More i&i Prague became a shareholder in the spin-off XENO Cell Innovations! Read More i&i Prague co-invested Dracen Pharmaceuticals, a company developing a novel oncology treatment Read More i&i Prague successfully mediated an out-licensing of antibodies from IMG Read More Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world Read More

Earlier News: 2020 We help inventions grow! BACK TO LATEST NEWS Nanofibers from Technical University of Liberec brings new hope in fight against Covid-19 Read More Enantis – first biotechnology spin-off from Masaryk University in Brno Read More DIANA Biotechnologies – technology that raised EUR 3M in 3 years Read More License for use of iBodies® bought by Immunotech, a member of the Beckman Coulter group! Read More LAM-X: revolutionary wound-treating nanomaterials Read More Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer Read More LAM-X – light-activated nanomaterials for face-masks and respirators Read More Elphogene: non-invasive screening of patients in advanced stages of cancer Read More DRACEN Pharmaceuticals – Novel glutamine antagonist as anticancer therapies Read More iBodies – synthetic antibodies from Institute of Organic Chemistry and Biochemistry of the CAS Read More Elphogene in World Journal of Gastroenterology! Read More Prague startup RIOCATH had recently entered market with its world-unique catheter! Read More Czech anti-covid19 #hackathon won by two i&i Prague accelerated projects Read More LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19 Read More iBodies established cooperation with Ximbio, a TTO within the UK’s largest charity, Cancer Research UK Read More LAM-X: the spin-off accelerated by i&i Prague in Media Read More

About us We focus on the transfer of new technologies into practice. We are dedicated to innovations in the field of Drug Discovery, Diagnostics, MedTech and other Life Science fields originating from academic institutions. Our team supports the creation of spin-off companies and the sale of licenses. Meet our team Our Mission We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. Our Objective Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region. Our Team Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them. Our background We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people. Meet our team Meet Our Team Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them. Jiří Moos CEO, Board of Directors Jiří Moos is the Executive Director of our bio-innovation center i&i Prague. Read More David Stíbal Vice Director David Stíbal is the Vice Director at i&i Prague. Read More Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. Read More Simona Šandová Office Manager Simona Šandová is the Office Manager of i&i Prague. Read More Milan Prášil Chairman, Board of directors Milan Prášil is the Chairman of the Board of Directors. Read More Jaromír Zahrádka Business development Jaromír Zahrádka is responsible for business development Read More Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. Read More Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. Read More Alexandr Krajhanzl Board of Directors Alexandr Krajhanzl has joined i&i Prague since September 2021. Read More Iva Machová Project Manager Iva Machová is a Project Manager at i&i Prague. Read More Martin Kovalčík Communications Martin Kovalčík is our Communications Manager. Read More

i&i Prague Bio-Innovation Center We are the first choice partner and the leading institution for the best early-phase biotech innovations and smart money investments. We focus on projects from Central Europe. Read more We are i&i Prague , a bio-innovation center located right in the heart of Europe. Our objective is to identify the potential of new inventions in Drug Discovery, Diagnostics, MedTech and other Life Science fields . We do this by scouting for innovative projects and investing in the most promising ones. Then we will help with product development and, ultimately, market entry. ​ We can help you with Investment With our investment, we try to help innovative ideas in their transition from research projects to functional companies. Read more Partnering We are creating a unique network of partners that brings a long-term exchange of innovative ideas and original experiences. Read more Incubation We are your new team member, leading your journey from groundbreaking invention to market-storming product. Read more Education We offer exciting educational activities that introduce important topics connecting the worlds of science and business. Read more Excellence & Knowledge We are the center of excellence and a knowledge base. Commercalization Partner We facilitate discussions between spin-offs and industry. Complex Support We are the center of complex support for the best of all projects. Our role Our portfolio We focus on unique ideas that have the potential to succeed on a global scale. We are dedicated to innovations in Drug Discovery, Diagnostics, MedTech and other Life Science fields that originate from academic institutions. Read more i&i Biotech Fund I In 2021, we established the i&i Biotech Fund in cooperation with the European Investment Fund. It is the venture capital firm that invests in innovative European Life Sciences companies focused on Drug Discovery, Diagnostics, MedTech and other Life Science fields. Read more Mar 11 2024 This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as Christian A. Stein, Petr Jansa, and other leading experts. The capital city of the Czech Republic is set to host the second Prague.bio Conference on September 24th 2024. The event unites top minds in biotechnology, representatives from major investment funds, technology transfer law specialists and other professionals from the biotech and medtech sectors. For ticket purchases, the project registration form and the latest news visit: www.conference.prague.bio . Read more Jan 30, 2024 CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours CasInvent Pharma, a university spin-off focused on developing anti-cancer compounds, has successfully closed the Pre-Series A funding round, raising a total of € 1.6 million from both existing and new investors. Founded in 2020 as a spin-off from Masaryk University in Brno and with the support of i&i Prague, CasInvent Pharma specializes in the development of highly selective inhibitors targeting the casein kinase 1 enzyme family.... Read more Nov 30, 2023 IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023 Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio)... Read more Feb 7, 2023 New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. ... Read more Highlights Read more i&i Prague in numbers 15 We have created or otherwise supported 15 spin-off companies from 5 countries . 9 We have an equity stake in 9 spin-offs . We have already announced 3 exits. 1.8 Overall, the spin-offs in our portfolio have raised more than CZK 1.8 billion from other investors. 15 We helped sell 15 licenses to universities and other academic institutions. Our partners To play, press and hold the enter key. To stop, release the enter key. Read more

< Back i&i Prague became a shareholder in the spin-off XENO Cell Innovations! XENO Cell Innovations is a young, progressing company based in Pilsen, Czech Republic. It is focused mostly on bio-computing – capturing complex biological system in images, combining creative microscopy with a little narration and a lot of imagination to make more visible the amazing potential of computing in liquid media. Their technology is able to link up to biological objects generating a coherent intelligible interface. It self-assembles into computational clusters and processes information locally within these clusters. Rather than relying on brute-force screening, the linked biological sample reports on itself. Categorically, a cluster is a physically connected network made up of genetically engineered yeast, linkers, enzymes, and other chemical modifiers. Clusters are not prefabricated. They self-assemble around objects with specific immunological profiles. By fusing different fluorescent labels to different yeast strains, the makeup of a cluster can in part be made visible. ​ We, the i&i Prague, had this great opportunity to offer our services to this project and helped its creators reach their goal. Now, with the company established, we became a proud shareholder! ​ The motto of XENO Cell Innovations is: „Many foundational problems in diagnostics and bioengineering are solvable if biology could just do more of the work. But current biotech isn’t smart enough. We are interested in changing the status quo by systematizing biologic units and constructing modular composition rules“ . ​ To find out more about this growing company, SEARCH: https://xenocells.com/ Previous Next

< Back Martin Kovalčík Communications For almost 13 years, Martin worked as a media coordinator for the respected Czech non-profit organization, People in Need, where he was responsible for the media service for a team of 300 people. Also, he has experience working in several editorial offices. He left his most significant mark at the Metro newspaper, where he worked for over 5 years, the last two as the deputy editor-in-chief.

< Back LAM-X a.s. is collaborating with TUL to develop active nanofilters against COVID-19 During COVID-19 crisis we embrace our startups to answer current questions and solve present problems. Our the most recently established startup – LAM-X, a.s. – is not an exception. LAM-X a.s., a technological spin-off of the Charles University and the Czech Academy of Sciences, joined forces with the Technical University of Liberec (TUL) in the fight against COVID-19. Their common goal is to develop active nanofilters that not only capture but also actively remove viral particles. The nanofilters will be useful as part of face masks and respirators. In response to the current situation, the LAM-X adapted its R&D strategy and began developing self-sterilizing filters usable as “active layers” of face masks and respirators. To increase production capacity, LAM-X, an academic spin-off, started cooperation with the Institute for Nanomaterials, Advanced Technologies and Innovation of the Technical University of Liberec. This institute is known for its excellent expertise in the production of nanomaterials. ​ “Cooperation with the academic environment is and will undoubtedly be very important for our company. After all, the LAM-X proprietary technology is based on many years of research by the academic group of Associate Professor Jiří Mosinger from the Faculty of Science of the Charles University,” said Dr. Chaloupka, the CEO of the company.“We believe that by starting cooperation with the Technical University of Liberec, the technology will be prepared faster for the industrial production”, mentioned Dr. Barbora Šumová, the board member representing company’s financial investor i&i Prague s.r.o She added: “Currently, there are almost no nanotechnologies that would offer active elimination of viral particles and those existing differ greatly in their effectiveness. To ensure high quality and smooth certification process, we therefore want to first thoroughly test our material in cooperation with the academic and private sectors.” ​ The use of LAM-X nanofilters offers additional added value. The amount of healthcare waste produced during this crisis will represent a significant economic and environmental burden on society. LAM-X self-sterilizing nanomaterials, that are intended for reuse, could at least partially alleviate this undesirable situation. ​ To learn more about this interesting project, contact barbora.sumova@lam-x.tech . Previous Next

About us We focus on the transfer of new technologies into practice. We are dedicated to innovations in the field of Drug Discovery, Diagnostics, MedTech and other Life Science fields originating from academic institutions. Our team supports the creation of spin-off companies and the sale of licenses. Meet our team Our Mission We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. Our Objective Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region. Our Team Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them. Our background We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people. Meet our team Meet Our Team Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them. Jiří Moos CEO, Board of Directors Jiří Moos is the Executive Director of our bio-innovation center i&i Prague. Read More David Stíbal Vice Director David Stíbal is the Vice Director at i&i Prague. Read More Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. Read More Simona Šandová Office Manager Simona Šandová is the Office Manager of i&i Prague. Read More Milan Prášil Chairman, Board of directors Milan Prášil is the Chairman of the Board of Directors. Read More Jaromír Zahrádka Business development Jaromír Zahrádka is responsible for business development Read More Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. Read More Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. Read More Alexandr Krajhanzl Board of Directors Alexandr Krajhanzl has joined i&i Prague since September 2021. Read More Iva Machová Project Manager Iva Machová is a Project Manager at i&i Prague. Read More Martin Kovalčík Communications Martin Kovalčík is our Communications Manager. Read More

Enantis, a Masaryk University spin-off company, concluded a license agreement for the production of stabilised growth factor FGF2. After months of negotiations, we are delighted to announce that Enantis, one of i&i Prague´s first supported start-ups, has entered into a global license agreement with one of the top providers of life science solutions with ther innovative FGF2-STAB® molecule and its use in research and cell therapy market. “Having a licensing deal with a company from Fortune magazine’s yearly list of 500 largest US companies is a significant milestone for us,” says Roman Badik, CEO of Enantis. Under the terms of agreement, Enantis along with Masaryk University have granted worldwide royalty-bearing license to manufacture FGF2-STAB® and develop new products containing this patented molecule. More details including the name of the licensee cannot be disclosed as per the terms of the license. ​ Enantis, Masaryk University’s first biotechnology spin-off company, has recently concluded a license agreement with a leading global distributor of materials for science and research. This will enable to increase the production of FGF2-STAB, a patented fibroblast growth factor, making it available to laboratories all over the world. Revenues from sales will also go to MU. ​ Growth factors are among the most important biomolecules in living cells. The synthesis and degradation of growth factors at the various stages of cell division and differentiation enable living organisms to develop and grow properly. Fibroblast growth factor 2 is among key molecules in cell cultivation media used to grow embryonic stem cells, which have broad applications in biomedical research and clinical practice. ​ Fibroblast growth factors are proteins supporting cell growth and division. Petr Dvořák and Pavel Krejčí from the Department of Biology at the Faculty of Medicine were among the first to work with these factors, focusing on FGF2. They discovered and characterised some of its properties, but more importantly, they managed to stabilise the factor using protein engineering. This means they modified it to remain functional for over twenty days at temperatures of around 37 degrees Celsius, which is critical for biological applications. ​ Leveraging their close co-operation with the teams at Loschmidt Laboratories, RECETOX, and the Department of Experimental Biology at the Faculty of Science, they agreed to test the newly developed FireProt stabilisation platform on these biomedically interesting but unstable molecules. “FireProt is a computational system that enables us to search for suitable modifications of molecules to make them useful in practice. FGF2 was the first system with applications in biomedicine on which we successfully used our platform,” said Jiří Damborský, describing the steps towards the recent success. ​ Modifications of FGF2 through protein engineering took three years and focused on the protein’s thermodynamic stability. “We gradually substituted certain amino acids in its structure for different ones, or in other words we deliberately created point mutations. This process strengthened the interactions between the amino acids, thus improving the overall robustness of the protein. The design of the mutations and their construction was quite fast, but then came a long period where we had to test their influence on the FGF2’s biological activity. We were very careful not to damage the protein, so we always tested only a single variant out of thousands of candidates,” added David Bednář, one of the creators of the FireProt platform. ​ Stabilised FGF2 can be used by scientists in their work with stem cells because it stimulates cell division and can be used in cell therapies, treatment of slow-healing wounds such as burns and in the treatment of diabetes. The molecule is protected by a patent that is jointly owned by MU and Enantis. The product named FGF2-STAB secured a European patent and patent proceedings in other countries are pending. ​ Enantis is responsible for the commercial applications of the molecule. After a year of negotiations, the company managed to conclude a license agreement with a US company which will manufacture and further develop the application possibilities of the growth factor. “The negotiation was not easy, but we’re happy that such an important global company decided to license our technology and satisfy the growing demand for our product,” said Roman Badík, CEO of Enantis. ​ While the name of the global company and other details of the license agreement have not been made public, it represents a breakthrough in the history of Masaryk University. “Each year, MU enters into dozens of licensing agreements for the intellectual property developed at the university. However, in terms of future benefits, this may be one of the most important contracts signed so far,” said Radoslav Trautmann, head of MU’s Technology Transfer Division, adding that it marks a milestone in biotechnology not only for the South Moravian Region, but the Czech Republic as a whole.

There’s Nothing Here... We can’t find the page you’re looking for. Check the URL, or head back home. Go Home

< Back Revolutionary type of catheter raised €2 million from private investors Czech company Riocath Global has introduced a worldwide unique technology applicable to tubular medical devices. This revolutionary technology has been patented and developed in collaboration with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences ( IOCB Prague ). The urinary catheter is one of the first clinically significant applications. The clinical trials will begin by the end of this year. The RIOCATH® (Reversal Inside-Out CATHetrisation) design greatly reduces the risk of introducing bacterial infection into the body. The current catheter is carrying on its surface microbes from the urethra tip as it makes its way through the urethra. Another danger is the damage to sensitive tissues caused by the insertion of current catheters. The new type of RIOCATH® urinary catheter will be of great benefit to a broad spectrum of patients. Reduction in bacterial infections should contribute significantly to reducing the need for antibiotic treatment. All of this should contribute to significant savings in the health care system and more comfortable patient care. “Unlike old catheters whose casing rubs on the urethra´s wall during insertion, the new technology allows for the catheter to extend by unfolding itself from the inside out, virtually imitating a snail´s eye stalk,” explains Miroslav Svoboda, MD, the project initiator, co-inventor and the CEO of Riocath Global. ​ “Upon completion of clinical trials and marketing of the catheter, the estimated value of the company will grow to tens of millions of euros. Apart from urinary catheters, the principal can be used in a number of other applications which are part of the company´s development portfolio with the considerable market and therapeutic potential,” comments on the importance of the patented technology Jaromír Zahrádka, PhD., the CEO of i&i Prague and a member of the board of directors of the Riocath Global. responsible for the intellectual property protection. The first product market entry is expected in 2019. ​ The full press release can be found here . Previous Next

< Back LAM-X: revolutionary wound-treating nanomaterials Story of LAM-X technology is a perfect example of our work in i&i Prague. For the last year our expert Investment manager Barbora Šumová entered project called LAM-X: light activated nanomaterials providing protection from bacteria, viruses and other patogenes. In cooperation with the university of origin (Charles University, Prague and CUIP) and the inventor doc. RNDr. Jiří Mosinger, PhD., Barbora helped LAM-X reach all milestones, build a proper business plan, set up a functional team and, finally, launched this advanced technology as a Start-up. Company itself was established on 20th February 2020. LAM-X is now a fully functional biotechnology company, it´s lead product is a nanomembrane that generates singlet oxygen upon activation by visible light. The clinical study on patients suffering from ulcers proved the efficacy of the LAM-X membrane. This platform technology can be used in the fight against infections that are caused by surface-transmitted pathogens found in hospitals, sanitation facilities, food and water production factories. Unlike antibiotics, which target specific cell parts, the singlet oxygen approach is quick and rather nonspecific, making it impossible for microbes to develop resistance mechanism. It can provide solution in countries, where sanitary conditions complicate even the simpliest medical interventions as well as it answers the general demand for non-antibiotic treatment, too. Previous Next